Repligen (RGEN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Voting matters and shareholder proposals
Shareholders will vote on the election of eight director nominees for the board for the upcoming term.
Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 is on the agenda.
An advisory vote will be held to approve the compensation paid to named executive officers.
The board may consider and act upon other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Eight nominees are proposed for election to the board, including individuals with diverse backgrounds and expertise.
Executive compensation and say-on-pay
Shareholders will have an advisory vote on the compensation of named executive officers, reflecting a say-on-pay policy.
Latest events from Repligen
- Board recommends re-electing directors, citing progress on internal controls and diversity.RGEN
Proxy filing27 Apr 2026 - Double-digit growth in FY25 with strong FY26 outlook and margin expansion despite headwinds.RGEN
Q4 202510 Apr 2026 - Proxy covers director elections, auditor ratification, executive pay, and strong 2025 growth.RGEN
Proxy filing2 Apr 2026 - Broad innovation, strong execution, and digital focus drive multi-year growth outlook.RGEN
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Bioprocessing leader targets $810M–$840M FY26 revenue and ~30% EBITDA margin by 2030.RGEN
Investor presentation10 Mar 2026 - 2026 outlook features robust growth, margin expansion, and strategic global investments.RGEN
Leerink Global Healthcare Conference 202610 Mar 2026 - Q2 revenue declined year-over-year, but order momentum and liquidity remain strong.RGEN
Q2 20242 Feb 2026 - Above-market growth driven by innovation, key accounts, and new modalities, with margin recovery ahead.RGEN
Jefferies Global Healthcare Conference1 Feb 2026 - Innovation, M&A, and advanced analytics drive growth amid protein headwinds and market recovery.RGEN
The 44th Annual William Blair Growth Stock Conference1 Feb 2026